Transcriptome profile of s-SHIP expressing breast cancer cells identifies PIERCE1 as a novel drug-resistance gene
Abstract
Triple-negative breast cancer is an aggressive subtype of breast cancer that is not sensitive to hormone inhibition. Its treatment is mainly limited to conventional therapies, including neoadjuvant chemotherapy. But the acquisition of drug resistance is a major obstacle to the eradication of the tumor cells, especially the breast cancer stem cells (BCSCs). Using a double-transgenic mouse model 11.5 kb-GFP x C3(1)-Tag, we have previously shown that s-SHIP expression identifies a breast cancer stem cell–related population in primary tumors. To investigate the chemoresistance of s-SHIP/GFP-expressing tumor cells, we used the MAM326 cell line, established from a tumor isolated from these double-transgenic mice. A subset of s-SHIP/GFP+ MAM326 cells, displaying a drug-tolerant stem-related phenotype, exhibited enhanced resistance to various chemotherapy drugs, including paclitaxel and doxorubicin. Transcriptomic analysis revealed that these s-SHIP/GFP+ cells exhibited upregulation of several genes associated with chemoresistance. Furthermore, this analysis highlighted Pierce1 which plays a role in DNA damage response. We showed that Pierce1 was significantly overexpressed in transiently surviving cells treated with paclitaxel and doxorubicin, both in MAM326 cells and in a primary tumoroid model. Overexpression of PIERCE1 in human TNBC SUM159PT cells led to increased resistance to chemotherapy, while its knockdown reduced this resistance. Importantly, clinical data further supported the association of high PIERCE1 expression with poor prognosis and reduced survival in TNBC patients treated with neoadjuvant chemotherapy. This study unveils the potential of PIERCE1 as a therapeutic target for overcoming chemotherapy resistance in breast cancer.
Related
- Single cell and spatial transcriptome profiling identifies KLF6 as a EMT driver in metastatic PTC
- Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy.
- Cross-cohort blood transcriptome analysis identifies an eight-gene diagnostic index and inflammatory programs in acute myocardial infarction
- Pretreatment Lactate Dehydrogenase-to-Albumin Ratio Identifies an Early Adverse Prognostic Profile in IDH-Wildtype Glioblastoma: A Real-World Cohort Study.
- Single-cell spatial transcriptomics identifies SERPINE1 as a vascular endothelial mediator of cisplatin resistance in head and neck squamous cell carcinoma.
BibTeX
@article{louvieaux2026transcriptome,
title = {{Transcriptome profile of s-SHIP expressing breast cancer cells identifies PIERCE1 as a novel drug-resistance gene}},
author = {Joséphine Louvieaux and Lu Tian and Alexandra Mougel and Axel Chomy and Nathan Laneret and Robert-Alain Toillon and Jérôme Vicogne and Xuefen Le Bourhis and Roland P. Bourette},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-73584-7},
url = {https://www.nature.com/articles/s41598-026-73584-7},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Transcriptome profile of s-SHIP expressing breast cancer cells identifies PIERCE1 as a novel drug-resistance gene
AU - Joséphine Louvieaux
AU - Lu Tian
AU - Alexandra Mougel
AU - Axel Chomy
AU - Nathan Laneret
AU - Robert-Alain Toillon
AU - Jérôme Vicogne
AU - Xuefen Le Bourhis
AU - Roland P. Bourette
PY - 2026
DA - 2026/10/02
JO - Scientific Reports
DO - 10.1038/s41598-026-73584-7
UR - https://www.nature.com/articles/s41598-026-73584-7
AB - Triple-negative breast cancer is an aggressive subtype of breast cancer that is not sensitive to hormone inhibition. Its treatment is mainly limited to conventional therapies, including neoadjuvant chemotherapy. But the acquisition of drug resistance is a major obstacle to the eradication of the tumor cells, especially the breast cancer stem cells (BCSCs). Using a double-transgenic mouse model 11.5 kb-GFP x C3(1)-Tag, we have previously shown that s-SHIP expression identifies a breast cancer stem cell–related population in primary tumors. To investigate the chemoresistance of s-SHIP/GFP-expressing tumor cells, we used the MAM326 cell line, established from a tumor isolated from these double-transgenic mice. A subset of s-SHIP/GFP+ MAM326 cells, displaying a drug-tolerant stem-related phenotype, exhibited enhanced resistance to various chemotherapy drugs, including paclitaxel and doxorubicin. Transcriptomic analysis revealed that these s-SHIP/GFP+ cells exhibited upregulation of several genes associated with chemoresistance. Furthermore, this analysis highlighted Pierce1 which plays a role in DNA damage response. We showed that Pierce1 was significantly overexpressed in transiently surviving cells treated with paclitaxel and doxorubicin, both in MAM326 cells and in a primary tumoroid model. Overexpression of PIERCE1 in human TNBC SUM159PT cells led to increased resistance to chemotherapy, while its knockdown reduced this resistance. Importantly, clinical data further supported the association of high PIERCE1 expression with poor prognosis and reduced survival in TNBC patients treated with neoadjuvant chemotherapy. This study unveils the potential of PIERCE1 as a therapeutic target for overcoming chemotherapy resistance in breast cancer.
SN - 2045-2322
ER -